+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 50Years +
All Genders
ID07516132

Long-Term Safety Study of OTX-TKI Axitinib Implant Injection in Adults 50 and Older with Neovascular Age-Related Macular Degeneration Participants Who Completed Previous 2-Year OTX-TKI Clinical Trials

Led by Ocular Therapeutix, Inc. · Updated on 2026-07-01

850

Participants Needed

8

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the long-term safety of an intravitreal implant called OTX-TKI Axitinib Implant in people with neovascular age-related macular degeneration nAMD who have successfully completed previous 2-year studies of this treatment. This phase 3b, open-label extension study focuses on participants who have already undergone either the OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 studies. The study aims to monitor any treatment-related adverse events and vision changes over an extended period. Participants will receive the OTX-TKI implant through an intravitreal injection directly into the eye. This study continues the evaluation of participants who completed previous OTX-TKI studies up to Weeks 96 or 104. The treatment is monitored over a long duration extending to Week 144 from the start of this study. The treatment and follow-up are designed to assess ongoing safety and vision outcomes. During the study, participants will be regularly evaluated for any treatment-emergent adverse events and the severity of vision loss using specific eye chart measurements. They must have adequate eye conditions to allow quality imaging and will attend scheduled visits to monitor their eye health and treatment effects. The study lasts until August 2030, with all safety and vision data carefully collected throughout this period to understand the long-term impact of the OTX-TKI implant.

CONDITIONS

Brief Title

Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study

Research Team

C

Clinical Project Manager

N

Nichole Wilkes

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here